Hyperliquid Strategies Inc and Sonnet BioTherapeutics Holdings, Inc. Announce Closing of Business Combination
Trading on The Nasdaq Capital Market under the ticker symbol “PURR”
| Date | Form | Description | XBRL | Pages | |
|---|---|---|---|---|---|
| 06/03/22 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
|
2 | |
| 06/02/22 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
|
2 | |
| 05/10/22 | S-8 | Initial registration statement for securities to be offered to employees pursuant to employee benefit plans |
|
6 | |
| 05/10/22 | 10-Q | Quarterly report pursuant to Section 13 or 15(d) |
|
   |
47 |
| 05/10/22 | 8-K | Current report filing |
|
|
4 |
| 04/13/22 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
|
3 | |
| 04/12/22 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
|
3 | |
| 04/12/22 | DEF 14A | Definitive proxy statements |
|
23 | |
| 04/11/22 | 8-K | Current report filing |
|
|
3 |
| 04/08/22 | 4 | Statement of changes in beneficial ownership of securities |
|
2 |
